NEOGENOMICS INC (NEO) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, NEOGENOMICS INC's filing signal turned negative.

NeoGenomics operates as a specialized oncology diagnostic testing and consultative services provider, with a network of CAP-accredited and CLIA-certified laboratories across the United States and one in the United Kingdom. The company offers a comprehensive suite of tests including cytogenetics, FISH, flow cytometry, IHC, molecular residual disease (MRD) testing, and next-generation sequencing (NGS). NeoGenomics serves a diverse client base, including community-based pathology and oncology practices, hospitals, academic centers, and pharmaceutical companies, providing both technical and professional components of testing. Its strategic focus is on expanding its market relevance in therapy selection and MRD testing, aiming to integrate precision oncology into community care settings.

Revenue is driven by clinical cancer testing, interpretation and consultative services, molecular and NGS testing, MRD testing, comprehensive technical and professional services, third-party clinical trials and research support, validation laboratory services, and oncology data solutions.